Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zmuda, Witold
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)	Recruiting	2	432	Europe, Canada, Japan, US, RoW	LY3540378, Placebo	Eli Lilly and Company	Heart Failure, Heart Failure With Preserved Ejection Fraction	11/25	01/26
Konrad, Matysiak
NCT04775706 / 2021-000176-11: Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects	Recruiting	2	18	Europe, US, RoW	HM15912 Active, Placebo	Hanmi Pharmaceutical Company Limited, Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd.	Short Bowel Syndrome	12/25	12/25
Beata, ziak
NCT04775706 / 2021-000176-11: Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects	Recruiting	2	18	Europe, US, RoW	HM15912 Active, Placebo	Hanmi Pharmaceutical Company Limited, Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd.	Short Bowel Syndrome	12/25	12/25
Olejniczak, Anna
NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria	Active, not recruiting	2	208	Europe, US, RoW	barzolvolimab, CDX-0159, Matching Placebo	Celldex Therapeutics	Chronic Spontaneous Urticaria	09/23	03/25
NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria	Active, not recruiting	2	196	Europe, US, RoW	barzolvolimab, CDX-0159, Matching Placebo	Celldex Therapeutics, Celldex Therapeutics, Inc.	Chronic Inducible Urticaria	06/24	10/24
NCT05292950 / 2022-003467-21: Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease	Recruiting	1	104	Europe, RoW	ARO-MUC5AC, Placebo	Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.	Asthma, Chronic Obstructive Pulmonary Disease	11/24	11/24
NCT05276570 / 2022-003466-20: Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease	Recruiting	1	149	Europe, RoW	ARO-RAGE, Placebo	Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc.	Asthma	12/24	02/25
Dzida, Radoslaw
NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria	Active, not recruiting	2	208	Europe, US, RoW	barzolvolimab, CDX-0159, Matching Placebo	Celldex Therapeutics	Chronic Spontaneous Urticaria	09/23	03/25
NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria	Active, not recruiting	2	196	Europe, US, RoW	barzolvolimab, CDX-0159, Matching Placebo	Celldex Therapeutics, Celldex Therapeutics, Inc.	Chronic Inducible Urticaria	06/24	10/24